 CRANBURY, N.J., Aug. 25, 2021 GLOBE NEWSWIRE -- -- Rafael Pharmaceuticals, Inc. Rafael or the Company, a leader in the growing field of cancer metabolism-based therapeutics, today announced the successful completion of a Phase 1b clinical trial of CPI-613 devimistat in combination with gemcitabine and cisplatin in patients with biliary tract cancer. In collaboration with Michigan Medicine , the Phase 1b study consisted of a multicenter trial of gemcitabine and cisplatin with devimistat as first-line therapy for patients with locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment. We are extremely excited and gratified to have completed Phase 1b and to be able to advance to the next phase Phase 2, said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. Advanced biliary tract cancer is a rare and aggressive cancer with a 5-year survival rate of less than 5, and the continuation of the trial aligns with our mission to help patients with significant unmet medical needs. 